Monoclonal Antibodies Market Analysis and Scope (2022 to 2028)
Monoclonal Antibodies Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 111.01 Billion |
| Market Size by 2028 | US$ 243.05 Billion |
| Global CAGR (2021 - 2028) | 11.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Source
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Monoclonal antibodies Market - Segmentation
Based on the source, the monoclonal antibodies market is segmented into human, humanized, chimeric, and murine. By production method, the market is segmented into in-vitro and in-vivo. The monoclonal antibodies market, by indication, is further segmented as cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, and others. By application, the market is subsegmented as therapeutic applications, diagnostic applications, and research applications. Furthermore, based on end-user, the market is segmented into hospitals, others, and research institutes..
Monoclonal antibodies Market - by Geography
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Amgen, Inc
- Daiichi Sankyo Company, Limited
- F. Hoffmann-La Roche AG
- AstraZeneca
- Elli Lily and Company
- Bayer AG
- Bristol-Myers Squibb Company
Get Free Sample For